Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended March 31, 2024 Or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ________ to ___________ (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) 31 East 62nd Street ...

NEW YORK, May 7, 2024 -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three months ended March 31, 2024. "SIGA delivered strong results in the first quarter, with product revenues of $24 million and pre-tax operating income of $11 million, both up over the comparable quarter in 2023," said Diem Nguyen, Chief Executive Officer. "First quarter financial performance is a testament to our focus on financial and operational exc ...

SIGA Technologies, Inc. (NASDAQ:SIGA) Q4 2023 Earnings Conference Call March 12, 2024 4:30 PM ET Company Participants Diem Nguyen - Chief Executive Officer Daniel Luckshire - Executive Vice President and Chief Financial Officer Conference Call Participants Soo Romanoff - Edison Group Lance Kimbrough - Ivy Creek Capital Operator Welcome to the SIGA Business Update Call. Before we turn the call over to SIGA management, please note that any forward-looking statements made during this call are based on manageme ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2023 Or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ________ to ___________ Commission File No. 0-23047 SIGA Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 13-38 ...

Exhibit 99.1 SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2023 NEW YORK -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and twelve months ended December 31, 2023. "In 2023, SIGA had approximately $131 million in product revenues and approximately $84 million of pre-tax operating income," stated Diem Nguyen, Chief Executive Officer. "These financial results represent a significant incr ...

SIGA Technologies, Inc. (NASDAQ:SIGA) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Phillip Louis Gomez - Chief Executive Officer Dennis Hruby - Executive Vice President and Chief Scientific Officer Jay Varma - Executive Vice President and Chief Medical Officer Daniel Luckshire - Executive Vice President and Chief Financial Officer Conference Call Participants Pooya Hemami - Edison Group Paul Saunders - Hatch Capital Operator Welcome to the SIGA business update call. Befo ...

(Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended September 30, 2023 Or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ________ to ___________ Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q New York, NY (zip code) (Address of principal executive offices) Commission File No. 0-23047 Delaware 13-3864870 ...

Financial Data and Key Metrics Changes - For the second quarter of 2023, the company reported a net loss of approximately $3 million, with a fully diluted loss per share of $0.04. For the six months ended June 30, the net loss was approximately $4 million, with a fully diluted loss per share of $0.05 [8][22][37] - The company expects to generate full-year 2023 pre-tax operating income between $90 million and $100 million, reflecting strong growth over the prior year [3][23] Business Line Data and Key Metrics Changes - Revenue for the three months ended June 30, 2023, was approximately $6 million, with $1 million from international sales of oral TPOXX and $5 million from research and development activities. For the six months ended June 30, total revenue was approximately $14 million [22][52] - The company anticipates approximately $113 million in revenue from deliveries of oral TPOXX to the US Strategic National Stockpile in the second half of 2023, along with an additional $30 million to $45 million from various domestic and international deliveries [17][52] Market Data and Key Metrics Changes - The company is seeing increased interest in international sales, with follow-on orders from countries and discussions about smallpox stockpiling [13][39] - The ongoing international sales growth initiative is progressing positively, indicating a meaningful international market is developing [24] Company Strategy and Development Direction - The company is focused on transitioning its US government contract to a long-term SNS contract, which will enhance supply chain planning and financial predictability [9] - The PEP-based development program is viewed as a growth initiative that may support stockpile expansion, emphasizing the need for proactive government measures in response to viral outbreaks [39][54] Management's Comments on Operating Environment and Future Outlook - Management highlighted the importance of TPOXX in treating orthopoxviruses, noting that the current stockpile may not be sufficient for future needs [53] - The company is investigating lower-than-expected immune response rates in clinical trials, which may affect the timing of regulatory submissions [19][49] Other Important Information - The company declared and paid a special cash dividend of $0.45 per share, totaling approximately $32 million [52] - The CEO search is ongoing, with a focus on ensuring a smooth transition for the next CEO [54] Q&A Session Summary Question: Incremental orders or stockpiling after 2024 under the 19C BARDA contract - Management indicated that discussions with the government are progressing, and they anticipate recognizing sales in the second half of the year [40][41] Question: Plans for stock buybacks - The company has $21 million remaining in its stock buyback authorization and will discuss next steps with the Board once this is used or expires [33] Question: International orders for smallpox and monkeypox stockpiling - Management confirmed that there is increased interest from international jurisdictions regarding stockpiling for smallpox and monkeypox [57]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended June 30, 2023 Or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ________ to ___________ Commission File No. 0-23047 SIGA Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 1 ...

SIGA Technologies, Inc. (NASDAQ:SIGA) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Phil Gomez - CEO Dennis Hruby - Chief Scientific Officer Dan Luckshire - CFO Conference Call Participants Adam McCarter - Edison Group Ralph Weil - R. Weil Investments Operator Welcome to the SIGA Business Update Call. Before we turn the call over to SIGA management, please note that any forward-looking statements made during this call are based on management's current expectations and observat ...